Back to Search Start Over

SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients

Source :
Renal & Urology News. December 15, 2022
Publication Year :
2022

Abstract

(HealthDay News) — For patients with diabetes subsequently diagnosed and hospitalized with COVID-19, use of a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) before COVID-19 infection is associated with lower COVID-19-related adverse outcomes, [...]

Subjects

Subjects :
Diabetes therapy -- Analysis
Medical colleges -- Analysis
Hypoglycemic agents -- Analysis
Diabetics -- Patient outcomes
Health

Details

Language :
English
ISSN :
15509478
Database :
Gale General OneFile
Journal :
Renal & Urology News
Publication Type :
Periodical
Accession number :
edsgcl.730154493

Tools

Authors Abstract Subjects Details